Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue. Now, researchers at UC San Francisco have found ...
Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...
Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue. Now, researchers at UC San Francisco have found ...
Akari Therapeutics has announced the issuance of Patent No. 562,919 for its PH1 payload, a differentiated spliceosome inhibitor aimed at disrupting RNA splicing to induce cancer cell death and ...
• Pre-mRNA splicing is an essential step for the regulation of gene expression. In order to specifically capture splicing variants in plants for genome-wide association studies (GWAS), we developed a ...
Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue. Immune therapy has transformed how cancer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback